Dr. Shusen Liu Joins GenomiCare Biotechnology as Chief Medical Officer
healthcaretechoutlook

Dr. Shusen Liu Joins GenomiCare Biotechnology as Chief Medical Officer

Healthcare Tech Outlook | Monday, February 14, 2022

Dr. Liu will oversee the development of global biopharmaceutical firm relationships and the use of real-world data (RWD).

FREMONT, CA: “We are pleased to welcome Dr. Shusen Liu to GenomiCare Biotechnology as Chief Medical Officer," states Dr. Qiang Xu, GenomiCares President and CEO. Dr. "Liu is a seasoned leader within the pharmaceutical industry and has long-term working experience with national regulatory institutions. With GenomiCares existing leadership in providing longitudinal, patient-centered care and comprehensive molecular profiling and clinical data, we are confident that his experience will broaden and accelerate the impact GenomiCares intelligent real world data solutions for the benefit of both patients and our pharmaceutical partners, alike." GenomiCare Biotechnology, a pioneer in precision medicine for Chinese cancer patients and the application of RWD to pharmaceutical research and development, has hired Shusen Liu, M.D., Ph.D., as Chief Medical Officer. Dr. Liu has extensive experience developing and leading RWD teams and implementing RWD in drug development and post-marketing review at multinational pharmaceutical companies, including MSD, Sanofi, and most recently, BMS. Dr. Liu is responsible for growing GenomiCares' cooperation with biotechnology and pharmaceutical businesses in China and abroad to offer revolutionary new treatments to cancer patients faster.

On his appointment, Dr. Liu states, “As Chief Medical Officer of GenomiCare Biotechnology, I am looking forward to taking advantage of my experience in the RWD research and making contributions to the RWD strategy and commercial expansion. GenomiCares truly unique RWD solution, with long-term engagement of cancer patients and their families, promises to accelerate the ability of global pharmaceutical companies to meet the critical unmet needs of patients and address many of the challenges facing oncology practice today.”

GenomiCare Biotechnology's RWD solutions for pharmaceutical firms leverage the clinical network it has created over the last six years, which includes over 200 hospitals and over 1,200 clinicians. GenomiCare is unique among RWD companies in that it works directly with patients and families to optimize their patient care by collecting and curating their complete clinical records, including state-of-the-art molecular profiling data from GenomiCare's CLIA/CAP-certified laboratory, and then providing quarterly follow-up calls to patients to provide support, information, and assurance that their medical records remain current.

Dr. Lius's previous positions within global pharmaceutical companies include Senior Director & Head, Real World Evidence & Epidemiology at BMS China; Senior Director & Head, Real World Evidence at Sanofi China; and Director & Head, Pharmacoepidemiology Asia Pacific Unit, Center for Observational and Real-World Evidence at MSD China. He has also worked at Digital China Health as Vice President and Chief Medical Evidence Officer (DCH).

Dr. Liu earned medical degrees from Shanghai Medical University and Fudan University and a Ph.D. in Epidemiology from UCLA. Additionally, he participated on the editorial board of Pharmacoepidemiology (Edition II) and contributed a chapter to the Practice of Evidence-based Medicine.

Weekly Brief